CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 10.6

ph-index = 2

Forward Citations = 31(Granted Patents)

Location History:

Melesse, FR (2008 - 2016)
Rennes, FR (2022)

Company Filing History:

Years Active: 2008-2024

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12134608 - Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands (2024-11-05),

2. 11306069 - Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands (2022-04-19),

3. 9255101 - 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands (2016-02-09),

4. 9242959 - (Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications (2016-01-26),

5. 9029357 - Benzazole derivatives as histamine H4 receptor ligands (2015-05-12),

6. 8802678 - [object Object] (2014-08-12),

7. 8802664 - Benzazole derivatives as histamine H4 receptor ligands (2014-08-12),

8. 7432269 - Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents (2008-10-07),

Title: Thierry Calmels: Innovator in Benzimidazole Derivatives

Introduction

Thierry Calmels is a notable inventor based in Melesse, France. He has made significant contributions to the field of medicinal chemistry, particularly through his work on benzimidazole derivatives. With a total of eight patents to his name, Calmels has established himself as a key figure in the development of dual histamine receptor ligands.

Latest Patents

Calmels' latest patents focus on novel benzimidazole enantiomeric derivatives. These compounds are designed to act as dual histamine H1 and H4 receptor ligands. The applications highlight the process of preparation and the therapeutic uses of these derivatives, showcasing their potential in treating various conditions.

Career Highlights

Throughout his career, Thierry Calmels has worked with prominent companies in the pharmaceutical industry, including Bioprojet and Bioproject. His expertise in medicinal chemistry has allowed him to contribute to innovative solutions in drug development.

Collaborations

Calmels has collaborated with several professionals in his field, including Isabelle Berrebi-Bertrand and Marc Capet. These partnerships have further enhanced his research and development efforts.

Conclusion

Thierry Calmels is a distinguished inventor whose work on benzimidazole derivatives has the potential to impact therapeutic practices significantly. His contributions to the field of medicinal chemistry are noteworthy and continue to inspire future innovations.

This text is generated by artificial intelligence and may not be accurate.